2. have inadequate recovery* from adverse events resulting from previously-administered anti-cancer therapies; [*Note: Unless more specifically defined in Inclusion Criteria 6, 7 and 8 above, adequate recovery is defined as improvement to ≤ Grade 2 for any other hematologic toxicity and for peripheral neuropathy, and improvement to ≤ Grade 1 for any other non-hematologic toxicity.]